Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Isatuximab Gets Priority Review for Transplant-Ineligible Multiple Myeloma
empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.